133
Participants
Start Date
August 31, 2013
Primary Completion Date
August 31, 2015
Study Completion Date
August 31, 2015
Clopidogrel
"A platelet aggregation inhibitor. Also a P2Y12 Receptor Blocker of a drug class Thienopyridine.~Increasing evidence has shown that clopidogrel has wide inter-individual variability in pharmacokinetic and pharmacodynamic actions which lead to suboptimal antiplatelet effect especially in Asian population.~A standard loading dose of 300mg or 600mg(according to clinical protocol) will be given to patients."
Ticagrelor
"A platelet aggregation inhibitor.~Though this agent has better anti-ischemic effects, it is associated with increased bleeding risk especially in Chinese patients whom are considered to be more prone to bleeding complications.~A loading dose of 180mg will be used."
Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Hospital Authority, Hong Kong
The University of Hong Kong
OTHER